3rd Apr 2018 11:08
The agreement relates to SkinBiotix, a proprietary platform technology that can improve the barrier effects of skin models, protect skin models from infection and repair skin models.
SkinBioTherapeutics has been in talks with a range of commercial partners ahead of its human studies which are due to commence later this year.
One partner has reached the material transfer agreement after SkinBioTherapeutics shared its initial pre-clinical data. The material transfer agreement provides for SkinBioTherapeutics to share a sample of its material against which the third party will conduct its own in-house assessment. Whilst at this stage there can be no certainty that discussions will progress further than the initial sharing of the technology.
"Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA [Material Transfer Agreement]. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry," SkinBioTherapeutics Chief Executive Cath O'Neill said.
Shares in SkinBioTherapeutics were trading up 9.4% at
Related Shares:
Skinbiotherap.